Emtricitabine + tenofovir alafenamide
Emtricitabine + tenofovir alafenamide has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Mar 26, 2026: “An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics”.
See all 4 papers on emtricitabine + tenofovir alafenamide
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Significant decreases were observed in DunedinPACE (−0.061, 95% CI: −0.11 to −0.01, p=0.019), indicating a measurable slowing of the pace of biological aging.”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Gilead Sciences and others
- 5 of 5 findings with company ties
- Human trial1
Studies in people
1 study gave emtricitabine + tenofovir alafenamide to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases DunedinPACE−0.061 (95% CI −0.11 to −0.01) down: Decreases PhenoAge−6.33 years (95% CI −10.91 to −1.74) down: Decreases IL-6−0.058 a.u. (95% CI −0.11 to −0.006) | Randomized trial12 weeks | 79 people18–50 yearsHealthy adults aged 18–50 years without HIV infection | medRxiv : the preprint server for health sciences, Mar 26, 2026 |
What did studies of emtricitabine + tenofovir alafenamide find?
4Studies of emtricitabine + tenofovir alafenamide measured 4 outcomes; the most studied are DunedinPACE (1 study), epigenetic IL-6 (1) and IL-6 (1).
DunedinPACE
downin humans1
1 study
DunedinPACE
downin humans1
Emtricitabine + tenofovir alafenamide decreases DunedinPACE in humans (FTC/TAF study arm) (-0.061 (DunedinPACE), p=0.019; -6.33 (PhenoAge), p=0.008).
“epigenetic aging measures based on DNA methylation (DNAm) profiling decreased over follow-up, including DunedinPACE (-0.061, p=0.019) and PhenoAge (-6.33, p=0.008)”
Human trialFTC/TAF study arm200 mg/25 mg12 weeksn = 36
medRxiv : the preprint server for health sciencesPreprint
Emtricitabine + tenofovir alafenamide decreases DunedinPACE in humans (−0.061 (95% CI −0.11 to −0.01)).
“Significant decreases were observed in DunedinPACE (−0.061, 95% CI: −0.11 to −0.01, p=0.019), indicating a measurable slowing of the pace of biological aging.”
Human trial12 weeksn = 36
medRxiv : the preprint server for health sciencesPreprint
Epigenetic IL-6
downin humans1
1 study
Epigenetic IL-6
downin humans1
Emtricitabine + tenofovir alafenamide decreases epigenetic IL-6 in humans (FTC/TAF study arm) (-0.058, p=0.029).
“significant reductions in epigenetic IL-6 (-0.058, p=0.029)”
Human trialFTC/TAF study arm200 mg/25 mg12 weeksn = 36
medRxiv : the preprint server for health sciencesPreprint
IL-6
downin humans1
1 study
IL-6
downin humans1
Emtricitabine + tenofovir alafenamide decreases IL-6 in humans (−0.058 a.u. (95% CI −0.11 to −0.006)).
“DNAm-derived IL-6 levels decreased significantly (−0.058 arbitrary unit (a.u.), 95% CI: −0.11 to −0.006, p=0.029), and DNAm C-reactive protein showed a trend toward reduction (−0.231 a.u., p=0.059).”
Human trial12 weeksn = 36
medRxiv : the preprint server for health sciencesPreprint
PhenoAge
downin humans1
1 study
PhenoAge
downin humans1
Emtricitabine + tenofovir alafenamide decreases PhenoAge in humans (−6.33 years (95% CI −10.91 to −1.74)).
“Among epigenetic clock-based measures, the second-generation epigenetic clock PhenoAge showed the largest effect (−6.33 years, 95% CI: −10.91 to −1.74, p=0.008), followed by AdaptAge (−5.92 years, p=0.027), first-generation epigenetic clock Horvath (−4.27 years, p=0.023), PCHorvath2 (−3.81 years, p=0.020), PCHorvath1 (−3.63 years, p=0.015), and SystemsAge (−3.49 years, p=0.008”
Human trial12 weeksn = 36
medRxiv : the preprint server for health sciencesPreprint